- About the INS
- About Neuromodulation
- For Patients
- News & Events
- Member Center
The International Neuromodulation Society
The Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of Neuromodulation
The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, explanatory content, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field.
The INS Peer-Reviewed Journal – 8 Issues a Year
The INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online.
Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application.
Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:
If you are not a medical professional and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.
Members may log in and visit the members-only section’s Global Discussion Forum
March 20, 2017 - International Neuromodulation Society members Leonardo Kapural, MD, PhD, John Chae, MD, Richard Rauck, MD, Michael Saulino, MD, Joseph Boggs, PhD and colleagues report in Pain Practice on two patients who received one month of peripheral nerve stimulation for chronic low back pain. They say the use of pain relievers dropped and the patient who had been taking opioids stopped, and the pain relief continued at least four months after therapy began. (Medical Xpress)
Journal Publishes a Long-Term Followup of Eight Patients with Depression who Received Deep Brain Stimulation
March 20, 2017 - Researchers in Germany report that seven of eight patients who received deep brain stimulation to the medial forebrain bundle for severe depression showed lasting improvements up to four years into treatment. The report appeared in the journal Brain Stimulation. (News-Medical.net)
March 20, 2017 - SetPoint Medical announced it has received an investment from the venture capital firm New Enterprise Associates (NEA), and NEA general partner Dr. Josh Makower has joined its board of directors. (Mass Device)
To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.
|Last Updated on Monday, December 12, 2016 10:01 AM|